Possibilities of the efficiency and safety control of rivaroxaban application in patients with atrial fibrillation
- Authors: Kryukov E.V.1, Prokofiev A.B.2, Danko A.A.2, Dmitriev A.I.2, Melnikov E.S.2, Rodina T.A.2, Belkov S.A.2
-
Affiliations:
- Military Medical Academy named after S.M. Kirov of the Ministry of Defense of the Russian Federation
- Scientific Center for Expertise of Medicinal Products, Ministry of Health of the Russian Federation
- Issue: Vol 23, No 2 (2021)
- Pages: 9-16
- Section: Clinical trials
- URL: https://journals.rcsi.science/1682-7392/article/view/64961
- DOI: https://doi.org/10.17816/brmma64961
- ID: 64961
Cite item
Abstract
The results of a study of the concentration of rivaroxaban in the peripheral blood in patients with atrial fibrillation, receiving different doses of rivaroxaban, as well as in the case of developing hemorrhagic complications, are presented. 65 patients admitted for treatment for atrial fibrillation were examined. As an anticoagulant drug, rivaroxaban was prescribed at a dose of 15 or 20 mg once a day, depending on the state of renal function. The patients were divided into 3 groups depending on the prescribed dose of rivaroxaban and the presence or absence of hemorrhagic complications. At the same time, each patient underwent therapeutic drug monitoring of the drug. It was found that in patients, who received rivaroxaban at a dose of 15 mg, in 35% of cases its concentration in the blood was below the average minimum values. In patients, who received the drug at a dose of 20 mg, in 16% of cases its concentration in the blood serum exceeded the average maximum values. Patients treated with 15 mg of rivaroxaban lacked any hemorrhagic complications. In the group of patients with advanced hemorrhagic complications who received rivaroxaban at a dose of 20 mg, its serum concentration at all stages of therapeutic drug monitoring was significantly higher than the average maximum values and more than 4 times higher than in the control group (without hemorrhagic complications). The results of the study indicate the advisability of conducting therapeutic drug monitoring with the determination of rivaroxaban concentrations in the blood serum of patients receiving the drug, especially when they develop hemorrhagic complications.
Full Text
##article.viewOnOriginalSite##About the authors
Evgeny V. Kryukov
Military Medical Academy named after S.M. Kirov of the Ministry of Defense of the Russian Federation
Author for correspondence.
Email: evgeniy.md@mail.ru
ORCID iD: 0000-0002-8396-1936
Scopus Author ID: 57208311867
doctor of medical sciences, professor
Russian Federation, Saint PetersburgAlexey B. Prokofiev
Scientific Center for Expertise of Medicinal Products, Ministry of Health of the Russian Federation
Email: andreida@mail.ru
doctor of medical sciences
Russian Federation, MoscowAndrey A. Danko
Scientific Center for Expertise of Medicinal Products, Ministry of Health of the Russian Federation
Email: andreida@mail.ru
candidate of medical sciences
Russian Federation, MoscowArtyom I. Dmitriev
Scientific Center for Expertise of Medicinal Products, Ministry of Health of the Russian Federation
Email: andreida@mail.ru
analyst
Russian Federation, MoscowEvgeny S. Melnikov
Scientific Center for Expertise of Medicinal Products, Ministry of Health of the Russian Federation
Email: andreida@mail.ru
candidate of pharmaceutical sciences
Russian Federation, MoscowTatyana A. Rodina
Scientific Center for Expertise of Medicinal Products, Ministry of Health of the Russian Federation
Email: andreida@mail.ru
candidate of chemical sciences
Russian Federation, MoscowSergey A. Belkov
Scientific Center for Expertise of Medicinal Products, Ministry of Health of the Russian Federation
Email: andreida@mail.ru
doctor of medical sciences, professor
Russian Federation, MoscowReferences
- Patel MR for ROCKET AF Executive Steering Committee. Stroke prevention using the oral direct factor Xa inhibitor rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation (ROCKET AF). Circulation. 2010;122(Suppl 21):2217.
- Wadelius M, Chen LY, Downes K, et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. The Pharmacogenomics Journal. 2005;5(4):262–270. doi: 10.1038/sj.tpj.6500313
- Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(20):263–272. doi: 10.1378/chest.09-1584
- ACC/AHA/ESC Guidelines for the Management of Patients with Atrial Fibrillation. Eur Heart J. 2010;31:2369–2429.
- Friberg J, Buch P, Scharling H, et al. Rising rates of hospital admissions for atrial fibrillation. Epidemiology. 2003;666–672. doi: 10.1097/01.ede.0000091649.26364.c0
- Levy S, Maarek M, Coumel P, et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. Circulation. 1999;99(23):3028–3035. doi: 10.1161/01.CIR.99.23.3028
- Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. Jama. 2001;285(18):2370–2375. doi: 10.1001/jama.285.18.2370
- Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004;110(9):1042–1046. doi: 10.1161/01.CIR.0000140263.20897.42
- Watson T, Shantsila E, Lip GYH. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. The Lancet. 2009;373(9658):155–166. doi: 10.1016/S0140-6736(09)60040-4
- Samsa GP, Matchar DB, Goldstein LB, et al. Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Archives of Internal Medicine. 2000;160(70):967–973. doi: 10.1001/archinte.160.7.967
- Developed with the special contribution of the European Heart Rhythm Association (EHRA) et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). European Heart Journal. 2010;31(19):2369–2429. doi: 10.1093/eurheartj/ehs253
- Authors/Task Force Members et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation developed with the special contribution of the European Heart Rhythm Association. European Heart Journal. 2012;33(21):2719–2747. doi: 10.1093/eurheartj/ehs253
- Sulimov VA, et al. Diagnostika i lechenie fibrillyacii predserdij. Rekomendacii RKO, VNOA i ASSH. Rossijskij kardiologicheskij zhurnal. 2013;18(4)S3:1–100. (In Russ.).
- January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Journal of the American College of Cardiology. 2014;64(21):e1–e76.
- Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Annals of Internal Medicine. 2007;146(120):857–867. doi: 10.7326/0003-4819-146-12-200706190-00007
- Connolly SJ, et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2009;361(12):1139–1151. doi: 10.1056/NEJMoa0905561
- Patel MR. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine. 2011;365(10):883–891. doi: 10.1056/NEJMoa1009638
- Beyer-Westendorf J, Foerster K, Pannach S, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood, The Journal of the American Society of Hematology. 2014;124(6):955–962. doi: 10.1182/blood-2014-03-563577
- Douxfils J, Gosselin RC. Laboratory assessment of direct oral anticoagulants. Seminars in thrombosis and hemostasis. Thieme Medical Publishers. 2017;43(03):277–290. doi: 10.1055/s-0036-1597296
- Cuker A, et al. Laboratory measurement of the anticoagulant activity of the non–vitamin K oral anticoagulants. Journal of the American College of Cardiology. 2014;64(11):1128–1139. doi: 10.1016/j.jacc.2014.05.065
- Rodina TA, et al. Development of an HPLC-MS/MS Method for Quantitative Determination of Rivaroxaban in Human Blood Serum. Pharmaceutical Chemistry Journal. 2018;52(4):372–377. doi: 10.1007/s11094-018-1824-3
- Noguez JH, Ritchie JC. Quantitation of the oral anticoagulants dabigatran, rivaroxaban, apixaban, and warfarin in plasma using ultra-performance liquid chromatography with tandem mass spectrometry (UPLC-MS/MS). Clinical Applications of Mass Spectrometry in Drug Analysis. Humana Press, New York, NY. 2016;21–27. doi: 10.1007/978-1-4939-3252-8_3
![](/img/style/loading.gif)